Function-related indicators
Function-related indicators has been studied in 2 papers since 2016: 2 observational studies in people. The newest paper, Aug 12, 2016: “Patient function, long-term survival, and use of surgery in patients with kidney cancer”.
2 papers study it5 findingsUpdated
See all 2 papers on function-related indicators
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country.
“Each additional FRI reduced the likelihood of receiving all three medication classes by 5% (adjusted odds ratio = 0.95, 95% confidence interval (CI) = 0.94-0.96)”
None of its findings points the other way.
- 2 independent labs in 1 country
- Funders: American Cancer Society and 4 more
- 2 of 5 findings with company ties
- Humans2
What did studies of function-related indicators find?
3Studies of function-related indicators measured 3 outcomes: cancer-directed surgery, kidney cancer mortality and use of all three secondary prevention medication classes.
Cancer-directed surgery
downin humans1OR 0.61
1 study
Cancer-directed surgery
downin humans1OR 0.61
Function-related indicators are linked with lower cancer-directed surgery in humans (2 or more function-related indicators versus none) (OR 0.61 (95% CI 0.56-0.66)).
“Patients with ≥ 2 indicators received cancer-directed surgery less often than those without disability (odds ratio, 0.61; 95% CI, 0.56-0.66)”
Humans2 or more function-related indicators versus none
Patient function, long-term survival, and use of surgery in patients with kidney cancer
Cancer
Kidney cancer mortality
no changein humans1
1 study
Kidney cancer mortality
no changein humans1
Function-related indicators were not clearly linked with kidney cancer mortality in humans (adjusted for patient and cancer characteristics).
“kidney cancer mortality varied minimally with patient function”
Humansadjusted for patient and cancer characteristics
Patient function, long-term survival, and use of surgery in patients with kidney cancer
Cancer
Use of all three secondary prevention medication classes
downin humans1
1 study
Use of all three secondary prevention medication classes
downin humans1
Function-related indicators are linked with lower use of all three secondary prevention medication classes in humans (per additional function-related indicator) (aOR 0.95 (95% CI 0.94-0.96) per additional FRI).
“Each additional FRI reduced the likelihood of receiving all three medication classes by 5% (adjusted odds ratio = 0.95, 95% confidence interval (CI) = 0.94-0.96)”
Humansper additional function-related indicatorn = 184,156
Journal of the American Geriatrics Society
What is function-related indicators linked with?
2Studies link function-related indicators with 2 measures: other-cause mortality and 12-month mortality.
Other-cause mortality
upin humans1HR 1.1
1 study
Other-cause mortality
upin humans1HR 1.1
Function-related indicators are linked with a higher risk of other-cause mortality in humans (adjusted for patient and cancer characteristics; indicator count compared with 0) (HR 1.10 (95% CI 1.04-1.16) for 1 indicator; HR 1.46 (95% CI 1.39-1.53) for 2 or more indicators).
“were found to have higher other-cause mortality”
Humansadjusted for patient and cancer characteristics; indicator count compared with 0
Patient function, long-term survival, and use of surgery in patients with kidney cancer
Cancer
12-month mortality
upin humans1
1 study
12-month mortality
upin humans1
Function-related indicators are linked with a higher risk of 12-month mortality in humans (per additional function-related indicator) (aHR 1.20 (95% CI 1.19-1.21) per additional FRI).
“and increased 12-month mortality by 20% (adjusted hazard ratio (aHR) = 1.20, 95% CI = 1.19-1.21)”
Humansper additional function-related indicator12 monthsn = 184,156
Journal of the American Geriatrics Society